Current Headlines

  1. Arcutis Submits Supplemental New Drug Application For ZORYVE® (Roflumilast) Cream 0.3% To Expand Indication For Treatment Of Plaque Psoriasis In Children Ages 2 to 5 9/3/2025

    Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2.

  2. Elsevier Launches PharmaPendium AI, Designed To Support Faster And More Reliable Access To Regulatory Insights For Drug Development 9/3/2025

    Elsevier, a global information and analytics company, today launches PharmaPendium AI, a generative AI assistant for regulatory intelligence in drug development. The solution transforms how regulatory affairs professionals, preclinical and clinical researchers access and apply information from US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory documents.

  3. Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development 9/3/2025

    Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale.

  4. Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-103, A Potential Best-In-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate 9/2/2025

    Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-103 (formerly VAC-103), a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate (ADC).

  5. Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals To Develop War-Lock Drug Conjugates And T-Cell Engagers For Improved Conditioning And Certain Autoimmune Diseases 9/2/2025

    Enlaza Therapeutics (“Enlaza” or the “Company”), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (“Vertex”) to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.

  6. BON Announces Identification Of Promising Weight-Managing Compounds From Tea via AI-Powered New Drug R&D Platform 9/2/2025

    Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a groundbreaking identification of a class of natural polyphenolic compounds from a tea-derived product via its AI-Powered new drug research and development (R&D) platform.

  7. Quotient Sciences And CPI To Accelerate RNA Drug Development With Joint Venture 9/2/2025

    Quotient Sciences announced a new partnership with the UK CPI (Centre for Process Innovation) to help accelerate mRNA therapeutics — combining CPI capabilities in LNP manufacturing and technology with Quotient Sciences' clinical and drug product development platform, Translational Pharmaceutics®.

  8. Norma Completes Quantum AI Algorithm Validation On NVIDIA 9/1/2025

    Quantum computing company Norma (CEO Hyunchul Jung, www.norma.co.kr) has achieved over 73× faster performance in drug development by running its quantum AI algorithm on NVIDIA GH200 Grace Hopper Superchips.

  9. Promising New Drug For People With Stubborn High Blood Pressure 8/30/2025

    A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

  10. Piramal Pharma Solutions Supports George Medicines In Developing Its New Drug For Hypertension, WIDAPLIK™ (telmisartan, amlodipine And indapamide) 8/28/2025

    George Medicines, a leading late-stage biopharma company, in partnership with Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635)developed WIDAPLIK, a new drug for treatment of hypertension in adult patients, including as initial treatment, to lower blood pressure.